Evgen Pharma PLC SAS study clarification (9987S)

TIDMEVG

RNS Number : 9987S

Evgen Pharma PLC

11 November 2019

Evgen Pharma plc

("Evgen Pharma" or the "Company")

SAS study clarification

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, provides the following clarification:

Further to this morning's earlier announcement, the Company can confirm that it remains well funded to pursue commercial opportunities for SFX-01 in oncology and other disease areas. Evgen is unlikely to pursue the subarachnoid haemorrhage opportunity given the data announced earlier today. The reference to a strategic review relates to the significance of these data on related neurological indications.

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                          via Walbrook 
 Dr Stephen Franklin, CEO 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                         [phone] 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane, Manasa Patil (ECM) 
 
 WG Partners LLP                                                 [phone] 
 Nigel Barnes / Claes Spång 
 
 Walbrook PR                             [phone] or [e-mail] 
                                                    [phone] / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                   741 001 
 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCEAAFFFEPNFFF

(END) Dow Jones Newswires

November 11, 2019 07:11 ET (12:11 GMT)